-
Je něco špatně v tomto záznamu ?
The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma
Z. Strizova, J. Bartunkova, D. Smrz,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, přehledy
Grantová podpora
364218
Grantová Agentura, Univerzita Karlova
PRIMUS/MED/12
Univerzita Karlova v Praze
AZV 16-28135A
Ministerstvo Zdravotnictví Ceské Republiky
NV16-28135A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
PubMed Central
od 1982
ProQuest Central
od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-04-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-03-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-03-01 do Před 1 rokem
- MeSH
- imunoterapie metody MeSH
- karcinom z renálních buněk patologie MeSH
- lidé MeSH
- míra přežití MeSH
- nádory ledvin patologie MeSH
- převzatá imunita metody MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Renal cell carcinoma (RCC) is one of the most lethal urologic malignancies. Its incidence continues to rise worldwide with a rate of 2% per year. Approximately, one-third of the RCC patients are diagnosed at advanced stages due to the asymptomatic nature of its early stages. This represents a great hurdle, since RCC is largely chemoresistant/radioresistant, and targeted therapy of mRCC still has limited efficacy. The 5-year survival rate of metastatic RCC (mRCC) is only around 10%. Adoptive cell transfer (ACT), a particular form of cell-based anticancer immunotherapy, is a promising approach in the treatment of mRCC. The vaccination principle, however, faces unique challenges that preclude the efficacy of ACT. In this article, we review the main challenges of ACT in the treatment of mRCC and describe multiple methods that can be used to overcome these challenges. In this respect, the ultimate purpose of this review is to provide a descriptive tool by which to improve the development of novel protocols for ACT of mRCC.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19044744
- 003
- CZ-PrNML
- 005
- 20200113104454.0
- 007
- ta
- 008
- 200109s2019 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00262-019-02359-z $2 doi
- 035 __
- $a (PubMed)31222485
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Strizova, Zuzana $u Institute of Immunology, 2nd Faculty of Medicine and Motol University Hospital, Charles University, V Uvalu 84, 150 06, Prague, Czech Republic.
- 245 14
- $a The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma / $c Z. Strizova, J. Bartunkova, D. Smrz,
- 520 9_
- $a Renal cell carcinoma (RCC) is one of the most lethal urologic malignancies. Its incidence continues to rise worldwide with a rate of 2% per year. Approximately, one-third of the RCC patients are diagnosed at advanced stages due to the asymptomatic nature of its early stages. This represents a great hurdle, since RCC is largely chemoresistant/radioresistant, and targeted therapy of mRCC still has limited efficacy. The 5-year survival rate of metastatic RCC (mRCC) is only around 10%. Adoptive cell transfer (ACT), a particular form of cell-based anticancer immunotherapy, is a promising approach in the treatment of mRCC. The vaccination principle, however, faces unique challenges that preclude the efficacy of ACT. In this article, we review the main challenges of ACT in the treatment of mRCC and describe multiple methods that can be used to overcome these challenges. In this respect, the ultimate purpose of this review is to provide a descriptive tool by which to improve the development of novel protocols for ACT of mRCC.
- 650 _2
- $a převzatá imunita $x metody $7 D019264
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a karcinom z renálních buněk $x patologie $7 D002292
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a nádory ledvin $x patologie $7 D007680
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bartunkova, Jirina $u Institute of Immunology, 2nd Faculty of Medicine and Motol University Hospital, Charles University, V Uvalu 84, 150 06, Prague, Czech Republic.
- 700 1_
- $a Smrz, Daniel $u Institute of Immunology, 2nd Faculty of Medicine and Motol University Hospital, Charles University, V Uvalu 84, 150 06, Prague, Czech Republic. daniel.smrz@lfmotol.cuni.cz.
- 773 0_
- $w MED00001041 $t Cancer immunology, immunotherapy : CII $x 1432-0851 $g Roč. 68, č. 11 (2019), s. 1831-1838
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31222485 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200113104826 $b ABA008
- 999 __
- $a ok $b bmc $g 1483013 $s 1083417
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 68 $c 11 $d 1831-1838 $e 20190620 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
- GRA __
- $a 364218 $p Grantová Agentura, Univerzita Karlova
- GRA __
- $a PRIMUS/MED/12 $p Univerzita Karlova v Praze
- GRA __
- $a AZV 16-28135A $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NV16-28135A $p MZ0
- LZP __
- $a Pubmed-20200109
